Factors Affecting Rapid Decline in Glomerular Filtration Rate in HIV/AIDS Patients Using Tenofovir Disoproxil Fumarate

Abstract

Introduction Tenofovir Disoproxil Fumarate (TDF) is a cornerstone of antiretroviral therapy for HIV/AIDS, but its use is associated with nephrotoxicity and a decline in glomerular filtration rate (GFR). Understanding the factors precipitating this renal dysfunction is critical for patient management. This literature review synthesizes recent evidence to identify the key factors affecting rapid GFR decline in HIV-infected patients on TDF-based regimens.

Methods This comprehensive literature review analyzes and synthesizes findings from seven key articles published between 2011 and 2012. The analysis includes cohort studies, consensus statements, and observational studies from diverse geographical settings, focusing on the identification of risk factors, prevalence of renal dysfunction, and mechanisms of TDF-induced nephrotoxicity.

Results TDF exposure is consistently associated with a decline in GFR, leading to acute kidney injury (AKI), chronic kidney disease (CKD), and Fanconi syndrome. Key risk factors identified across multiple studies include older age, lower body weight, and low CD4 count. Cumulative TDF exposure is highlighted as an independent predictor of chronic renal impairment. The underlying mechanism is primarily attributed to TDF accumulation in proximal renal tubular cells, causing mitochondrial toxicity and apoptosis.

Discussion The synthesized evidence indicates that the risk of TDF-induced nephrotoxicity is multifactorial and not uniform across all patients. The interplay between patient-specific factors (age, weight), disease-specific factors (CD4 count), and treatment-related factors (cumulative exposure) necessitates a personalized approach to risk assessment. This challenges a one-size-fits-all management strategy and underscores the need for vigilant, individualized monitoring.

Conclusion Vigilant and regular monitoring of renal function is essential for all HIV-infected patients receiving TDF-based therapy. Clinicians must consider a combination of risk factors, including cumulative exposure, age, and body weight, to identify at-risk individuals and mitigate the potential for a rapid decline in GFR, thereby ensuring the long-term safety of antiretroviral treatment.